Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LXEO Lexeo Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: LXEO
Price (delayed)
$2.83
Market cap
$93.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.3
Enterprise value
$71.19M
We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. By taking aim at the underlying genetic
Highlights
The debt has contracted by 16% YoY and by 5% from the previous quarter
The EPS has dropped by 108% year-on-year and by 7% since the previous quarter
The quick ratio has dropped by 64% year-on-year and by 39% since the previous quarter
Key stats
What are the main financial stats of LXEO
Market
Valuations
Earnings
Shares outstanding
33.2M
Market cap
$93.95M
Enterprise value
$71.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.07
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$116.28M
Net income
-$109.31M
EBIT
-$109.18M
EBITDA
-$107.15M
Free cash flow
-$88.3M
Per share
Balance sheet
Liquidity
EPS
-$3.3
EPS diluted
-$3.3
Free cash flow per share
-$2.67
Book value per share
$2.65
Revenue per share
$0
TBVPS
$3.8
Total assets
$125.69M
Total liabilities
$37.58M
Debt
$9.4M
Equity
$88.12M
Working capital
$74.45M
Debt to equity
0.11
Current ratio
3.42
Quick ratio
3.34
Net debt/EBITDA
0.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-68.5%
Return on equity
-85.9%
Return on invested capital
-255.7%
Return on capital employed
-115.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LXEO stock price
How has the Lexeo Therapeutics stock price performed over time
Intraday
7.6%
1 week
-12.92%
1 month
42.93%
1 year
-79.13%
YTD
-56.99%
QTD
-18.44%
Financial performance
How have Lexeo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$116.28M
Net income
-$109.31M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 60% YoY and by 10% from the previous quarter
LXEO's net income has shrunk by 57% YoY and by 11% QoQ
Price vs fundamentals
How does LXEO's price correlate with its fundamentals
Growth
What is Lexeo Therapeutics's growth rate over time
Valuation
What is Lexeo Therapeutics stock price valuation
P/E
N/A
P/B
1.07
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 108% year-on-year and by 7% since the previous quarter
LXEO's equity has dropped by 52% year-on-year and by 25% since the previous quarter
The P/B is 49% below the last 4 quarters average of 2.1
Efficiency
How efficient is Lexeo Therapeutics business performance
Lexeo Therapeutics's ROIC has soared by 65% YoY and by 33% from the previous quarter
Lexeo Therapeutics's return on equity has decreased by 32% QoQ
The ROA has contracted by 26% from the previous quarter and by 17% YoY
Dividends
What is LXEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LXEO.
Financial health
How did Lexeo Therapeutics financials performed over time
The quick ratio has dropped by 64% year-on-year and by 39% since the previous quarter
Lexeo Therapeutics's current ratio has plunged by 63% YoY and by 38% from the previous quarter
The debt is 89% less than the equity
The debt to equity has soared by 83% YoY and by 38% from the previous quarter
LXEO's equity has dropped by 52% year-on-year and by 25% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.